Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in November:
- Credit Suisse 31st Annual Healthcare Conference
Presentation date and time: Tuesday, November 8 at 11:25 – 11:55 a.m. ET - Piper Sandler 34th Annual Healthcare Conference
Fireside chat date and time: Wednesday, November 30 at 4:30 – 4:55 p.m. ET
The events will be webcast live and may be accessed via a link in the Investors section of the Nurix website under . An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For additional information visit .
Contacts:
Investors
Silinda Neou
Nurix Therapeutics
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
Media
Brett Whelan
LifeSci Communications
